Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: Perampanel (PER) is indicated as adjunctive antiseizure medication (ASM) in adolescents and adults with epilepsy. Data from clinical trials show good efficacy and tolerability, while limited information is available on the routine clinical use of PER, especially when used as only add-on treatment.
Methods: We performed an observational, retrospective, multicenter study on people with focal or generalized epilepsy aged >12 years, consecutively recruited from 52 Italian epilepsy centers. All patients received PER as the only add-on treatment to a background ASM according to standard clinical practice. Retention rate, seizure frequency, and adverse events were recorded at 3, 6, and 12 months after PER introduction. Subanalyses by early or late use of PER and by concomitant ASM were also conducted.
Results: Five hundred and three patients were included (age 36.5 ± 19.9 years). Eighty-one percent had focal epilepsy. Overall, the retention rate was very high in the whole group (89% at 12 months) according with efficacy measures. No major differences were observed in the subanalyses, although patients who used PER as early add-on, as compared with late add-on, more often reached early seizure freedom at 3-month follow-up (66% vs 53%, P = .05). Treatment-emergent adverse events occurred in 25%, far less commonly than in PER randomized trials.
Significance: This study confirms the good efficacy and safety of PER for focal or generalized epilepsy in real-life conditions. We provide robust data about its effectiveness as only add-on treatment even in patients with a long-standing history of epilepsy and previously treated with many ASMs.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712478 | PMC |
| http://dx.doi.org/10.1002/epi4.12649 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neuroimaging Findings in Children and Young Adults With Neurotoxicity After CAR T-Cell Therapy for B-Cell Malignancies.
Neurology
October 2025
Norcliffe Foundation Center for Integrative Brain Research, Seattle Children's Research Institute, WA.
Background And Objectives: Neuroimaging findings in immune effector cell-associated neurotoxicity syndrome (ICANS) have not been systematically described. We created the chimeric antigen receptor (CAR) T-cell Neurotoxicity Imaging Virtual Archive Library (CARNIVAL), a centralized imaging database for children and young adults receiving CAR T-cell therapy. Objectives of this study were to (1) characterize neuroimaging findings associated with ICANS and (2) determine whether specific ICANS-related neuroimaging findings are associated with individual neurologic symptoms.
View Article and Find Full Text PDFBackground: Oesophageal squamous cell carcinoma is the predominant histopathological subtype of oesophageal cancer across the world, representing as many as 90% of all cases; however, within Western cohorts, it is a low-prevalence disease, and, as such, appropriately powered trials to establish a standard treatment paradigm in this population remain challenging. The aim of this study was to assess current practices and compare outcomes for patients with locally advanced oesophageal squamous cell carcinoma across the UK and Ireland.
Methods: This was a retrospective multicentre cohort study of patients managed with curative intent for squamous cell carcinoma of the middle or distal oesophagus in 23 hospitals across the UK and Ireland.
Artificial intelligence-based CT histogram parameters differentiating bronchiolar adenoma and lung adenocarcinomas: A two-center study.
PLoS One
September 2025
Department of Radiology, the Third Affiliated Hospital of Kunming Medical University, Yunnan, Kunming, China.
Purpose: Bronchiolar adenoma (BA) is a rare benign pulmonary neoplasm originating from the bronchial mucosal epithelium and mimics lung adenocarcinoma (LAC) both radiographically and microscopically. This study aimed to develop a nomogram for distinguishing BA from LAC by integrating clinical characteristics and artificial intelligence (AI)-derived histogram parameters across two medical centers.
Methods: This retrospective study included 215 patients with diagnoses confirmed by postoperative pathology from two medical centers.
Outcomes of Multi-Organ Donation Recipients Following Prioritized Facial Vascular Composite Allograft Procurement.
Plast Reconstr Surg
September 2025
Hansjörg Wyss Department of Plastic Surgery, New York University Langone Health, New York, NY, US.
Background: Facial transplantation offers transformative solutions for patients with severe facial disfigurements. Minimizing ischemia time is critical for preserving tissue viability, and prioritizing facial allograft recovery during multi-organ procurement aims to optimize outcomes. This study evaluates whether prioritizing face allograft procurement affects the outcomes of non-vascularized composite allotransplantation (non-VCA) organ transplants.
View Article and Find Full Text PDFComparative evaluation of the CGuard dual-layer stent and Carotid Wallstent for elective carotid artery stenting: a retrospective multicenter study.
Neuroradiology
September 2025
Department of Diagnostic and Interventional Neuroradiology, Klinikum Solingen, Solingen, Germany.
Purpose: This study aims to evaluate the safety and efficacy of the CGuard dual-layer stent with its mesh embolic protection system (EPS) in elective cases for treatment of internal carotid artery stenosis and compares it to the Carotid Wallstent as benchmark.
Methods: In this retrospective, multicenter study, we analyzed data from consecutive patients who underwent carotid artery stenting with CGuard at two high-volume neurointerventional centers and compared them with prior consecutive patients treated with Carotid Wallstent (CWS), with and without a balloon guiding catheter (BGC) as protection, at the same institutions. Patient demographics, procedural details, clinical complications, early in-stent thrombosis and occlusion rates, and late follow-up restenosis rates were assessed.